Virus plus immunotherapy shows promise against resistant ovarian cancer
NCT ID NCT05271318
First seen Nov 03, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This early-stage trial tests a specially designed virus (TILT-123) that targets and kills cancer cells while also boosting the immune system. It is given together with the immunotherapy drug pembrolizumab (Keytruda) and sometimes chemotherapy, to women with ovarian cancer that no longer responds to platinum-based treatments. The main goal is to check safety and find the best dose in 29 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Docrates Cancer Center
Helsinki, 00180, Finland
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Northwell Heatlh/Lenox Hill Hospital
New York, New York, 10075, United States
Conditions
Explore the condition pages connected to this study.